[go: up one dir, main page]

NO20032441D0 - Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer - Google Patents

Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer

Info

Publication number
NO20032441D0
NO20032441D0 NO20032441A NO20032441A NO20032441D0 NO 20032441 D0 NO20032441 D0 NO 20032441D0 NO 20032441 A NO20032441 A NO 20032441A NO 20032441 A NO20032441 A NO 20032441A NO 20032441 D0 NO20032441 D0 NO 20032441D0
Authority
NO
Norway
Prior art keywords
combination
dehydrogenase inhibitors
sorbitol dehydrogenase
gaba agonists
gaba
Prior art date
Application number
NO20032441A
Other languages
English (en)
Other versions
NO20032441L (no
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20032441D0 publication Critical patent/NO20032441D0/no
Publication of NO20032441L publication Critical patent/NO20032441L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20032441A 2000-11-30 2003-05-28 Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer NO20032441L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
NO20032441D0 true NO20032441D0 (no) 2003-05-28
NO20032441L NO20032441L (no) 2003-07-03

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032441A NO20032441L (no) 2000-11-30 2003-05-28 Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer

Country Status (38)

Country Link
US (1) US6544998B2 (no)
EP (1) EP1337271B1 (no)
JP (1) JP2004514699A (no)
KR (1) KR20030059290A (no)
CN (1) CN1477975A (no)
AP (1) AP2001002360A0 (no)
AR (1) AR031431A1 (no)
AT (1) ATE281181T1 (no)
AU (1) AU2002215159A1 (no)
BG (1) BG107774A (no)
BR (1) BR0115783A (no)
CA (1) CA2430298A1 (no)
CR (1) CR6964A (no)
CZ (1) CZ20031399A3 (no)
DE (1) DE60106968T2 (no)
DO (1) DOP2001000289A (no)
EA (1) EA200300432A1 (no)
EC (1) ECSP034624A (no)
EE (1) EE200300248A (no)
ES (1) ES2230378T3 (no)
HR (1) HRP20030420A2 (no)
HU (1) HUP0302160A3 (no)
IL (1) IL155704A0 (no)
IS (1) IS6786A (no)
MA (1) MA26964A1 (no)
MX (1) MXPA03004870A (no)
NO (1) NO20032441L (no)
OA (1) OA12534A (no)
PA (1) PA8534101A1 (no)
PE (1) PE20020597A1 (no)
PL (1) PL365927A1 (no)
PT (1) PT1337271E (no)
SK (1) SK6192003A3 (no)
SV (1) SV2003000751A (no)
TN (1) TNSN01169A1 (no)
UY (1) UY27042A1 (no)
WO (1) WO2002043762A2 (no)
ZA (1) ZA200303381B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
CZ299755B6 (cs) * 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
EP1729740A2 (en) * 2004-04-02 2006-12-13 Impax Laboratories, Inc. PHARMACEUTICAL DOSAGE FORMS HAVING IMMEDIATE RELEASE AND/OR CONTROLLED RELEASE PROPERTIES THAT CONTAIN A GABA<SB>B</SB> RECEPTOR AGONIST
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
KR101063663B1 (ko) 2005-02-17 2011-09-07 아스텔라스세이야쿠 가부시키가이샤 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
MY148657A (en) 2007-04-27 2013-05-15 Purdue Pharma Lp Trpv1 antagonists and uses thereof
AU2008310114B2 (en) * 2007-10-09 2014-01-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN103228142A (zh) * 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20220169668A1 (en) 2019-04-17 2022-06-02 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
EP0059987B1 (en) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((n-guanidino)-imino) toluenes
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
TR200102810T2 (tr) * 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler

Also Published As

Publication number Publication date
SK6192003A3 (en) 2004-07-07
JP2004514699A (ja) 2004-05-20
AR031431A1 (es) 2003-09-24
IL155704A0 (en) 2003-11-23
PT1337271E (pt) 2005-01-31
ES2230378T3 (es) 2005-05-01
UY27042A1 (es) 2002-07-31
EE200300248A (et) 2003-10-15
MXPA03004870A (es) 2003-08-19
PA8534101A1 (es) 2002-10-31
WO2002043762A2 (en) 2002-06-06
HUP0302160A2 (hu) 2003-11-28
DE60106968D1 (de) 2004-12-09
TNSN01169A1 (fr) 2005-11-10
CZ20031399A3 (cs) 2004-04-14
US6544998B2 (en) 2003-04-08
PL365927A1 (en) 2005-01-10
ATE281181T1 (de) 2004-11-15
PE20020597A1 (es) 2002-07-08
US20020091128A1 (en) 2002-07-11
KR20030059290A (ko) 2003-07-07
ECSP034624A (es) 2003-07-25
ZA200303381B (en) 2004-04-30
CN1477975A (zh) 2004-02-25
SV2003000751A (es) 2003-01-13
BR0115783A (pt) 2003-09-16
AP2001002360A0 (en) 2001-12-31
OA12534A (en) 2006-06-05
IS6786A (is) 2003-04-14
HUP0302160A3 (en) 2005-05-30
BG107774A (en) 2004-01-30
AU2002215159A1 (en) 2002-06-11
WO2002043762A3 (en) 2003-03-13
MA26964A1 (fr) 2004-12-20
DOP2001000289A (es) 2003-02-15
NO20032441L (no) 2003-07-03
EP1337271B1 (en) 2004-11-03
HRP20030420A2 (en) 2004-08-31
CA2430298A1 (en) 2002-06-06
CR6964A (es) 2004-02-02
EA200300432A1 (ru) 2003-10-30
EP1337271A2 (en) 2003-08-27
DE60106968T2 (de) 2005-11-03

Similar Documents

Publication Publication Date Title
NO20032441D0 (no) Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer
NO20032387D0 (no) Kombinasjon av GABA agonister og aldose reduktase inhibitorer
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20052469D0 (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
CY2015053I2 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
GB0025782D0 (en) Use of inhibitors
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
IS6759A (is) Ný þíadíasól og oxadíasól og notkun þeirra sem fosfórdíesterasa-7 hindra
NO20020287L (no) Prodroge av en ICE-inhibitor
NO20015274D0 (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20020326L (no) Sammensetning og anvendelse av en inhibitor av PPAR-delta-aktivitet
NO20014770D0 (no) Assosiasjon av NO-syntase inhibitor(er) og metabolske antioksidanter
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
AU1212002A (en) Use of lipase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application